Mersana Therapeutics, Inc.: Nasdaq/NYSE listing notice — Mersana Therapeutics receives Nasdaq delisting notice for bid price non-compliance

Mersana Therapeutics, Inc.

Notice on Feb 25, 2025 for failure to maintain $1.00 minimum bid for 30 consecutive business days.
Company has 180 days (until Aug 25, 2025) to regain compliance by closing bid >=$1.00 for 10 consecutive days.
If not compliant, may get second 180-day period by moving to Nasdaq Capital Market and considering reverse stock split.
No immediate effect on listing or trading of MRSN common stock.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Mersana Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 25, 2025, Mersana Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1) because the Company has not maintained a minimum closing bid price of the Company’s common stock of at least $1.00 per share for the last 30 consecutive business days (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. In accordance with Nasda

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-25-019146

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.